Germany approves first new corona vaccine clinical trial

　　MEDICINENETWORK, April 23 (Upi) -- The Paul Ehrlich Institute, Germany's federal vaccine regulator, announced Tuesday that it has approved the country's first clinical trial of a new coronavirus vaccine The head of the agency, Mr Sichutke, said there was no prospect of a vaccine being approved for public injection this year Paul Ehrlich Institute said in a statement the same day, approved for clinical trials is the German company BioNTech developed an RNA (ribonucleic acid) vaccine The approved Phase I clinical trial will recruit 200 subjects between the ages of 18 and 55 After observing the first group of subjects for some time, a second phase of the second batch of subjects with the same age range was conducted The second phase of the trial is expected to include more subjects at high or high risk of severe infection 　　BioNTech said the same day, the "BNT162" vaccine is its joint development with pfizer, the United States, after the U.S regulatory approval, is expected to soon be put into clinical trials in the United States Paul Ehrlich Institute director Sichutek said the same day, this year is not expected to have the first approved, and available for the public injection of the new coronavirus vaccine 22, the cumulative number of confirmed infections in Germany has exceeded 150,000 As of 20:52 local time on the 22nd, germany has confirmed a total of 15,085 people, cured 91612, and died 5,247 people, according to Germany's Time Online (Complete)